REBYOTA®, CDI and IBS

REBYOTA® (fecal microbiota, live-jslm) is an FDA-approved microbiota-based therapy designed to prevent recurrent Clostridioides difficile infection (rCDI). The PUNCH CD3-OLS trial explored its safety and efficacy in patients with both rCDI and irritable bowel syndrome (IBS), a population often excluded from rCDI studies due to overlapping symptoms like diarrhea and abdominal pain. IBS is linked to gut microbiome imbalances, making microbiota restoration with REBYOTA® a promising therapeutic approach.

The study involved 697 participants, 90 of whom had IBS. Patients received a single rectal dose of REBYOTA® after completing standard antibiotic treatment for CDI. IBS participants had high rates of prior CDI episodes (70% had ≥3 episodes), highlighting their complex medical history. Despite this, REBYOTA® demonstrated robust efficacy: 68.9% of IBS patients achieved treatment success at 8 weeks, defined as the absence of CDI diarrhea, and 82.3% maintained remission for 6 months.

Safety outcomes were favorable, with most treatment-emergent adverse events (TEAEs) being mild or moderate. IBS patients reported slightly higher gastrointestinal TEAEs (e.g., diarrhea, nausea), likely reflecting baseline IBS symptoms rather than treatment complications. Serious adverse events were rare and unrelated to REBYOTA®.

REBYOTA® effectively restored microbial diversity, reducing CDI recurrence risk and addressing microbiota-related IBS vulnerabilities. While the trial was open-label and lacked IBS subtype data, findings support expanding microbiota-based therapies to complex populations like IBS patients with rCDI. REBYOTA® offers a safe, well-tolerated, and effective option for improving outcomes in these challenging cases.